We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.The Big Biz Show covers current business events, internet-related issues and other hot topics in the business world. Also, they are expecting to begin human trials on GPX-001 FDA Fast Track Mid 2020. Through the license, Genprex will add the Pitt technology to its research and development pipeline in an effort to diversify its portfolio and expand its clinical development programs. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission.
Also, they are expecting to begin human trials on GPX-001 FDA Fast Track Mid 2020.
The MarketWatch News Department was not involved in the creation of this content. Genprex appears live on the Big Biz Show for a second timeDuring this interview, Mr. Varner discusses:Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. With all the research on diabetes and advances in diabetes treatments, it's tempting to think someone has surely found a diabetes cure by now. Genprex issues a letter to shareholders, providing corporate and clinical updates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The Emmy Award winning show was named by TALKERS Magazine as one of the “Top 10 Most Influential Financial Shows.” The Big Biz Show is seen and heard in over 100 million broadcast TV homes, 150 radio stations in the U.S. and in 175 countries. Such statements include, but are not limited to, statements regarding the effects of the licensed gene therapy on diabetes and the effect of Genprex’s other product candidates, alone and in combination with other therapies, on cancer, as well as Genprex’s ongoing and planned preclinical and clinical studies and potential partnerships. All forward-looking statements contained in this press release speak only as of the date on which they were made. According to Gittes, that time period could translate to decades in humans.